Lexicon Pharmaceuticals (LXRX) Insider Trading & Ownership $0.80 -0.01 (-1.16%) (As of 12:45 PM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Lexicon Pharmaceuticals (NASDAQ:LXRX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage6.80%Number OfInsiders Buying(Last 3 Years)5Amount OfInsider Buying(Last 3 Years)$113.70 MNumber OfInsiders Selling(Last 3 Years)0 Get LXRX Insider Trade Alerts Want to know when executives and insiders are buying or selling Lexicon Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address LXRX Insider Buying and Selling by Quarter Ad DarwinNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Lexicon Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/16/2023Lonnel CoatsCEOBuy90,000$1.05$94,500.00 11/10/2023Lonnel CoatsCEOBuy10,000$1.01$10,100.00 10/12/2023Raymond DebbaneDirectorBuy148,820$1.03$153,284.60 10/10/2023Raymond DebbaneDirectorBuy508,306$1.14$579,468.84 9/14/2023Jeffrey L WadeCFOBuy10,000$1.38$13,800.00 8/4/2023Wendy McdermottVPBuy6,000$1.84$11,040.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 6/29/2023Lonnel CoatsCEOBuy10,000$2.16$21,600.00 6/26/2023Lonnel CoatsCEOBuy10,000$2.18$21,800.00 6/23/2023Wendy McdermottVPBuy10,000$2.43$24,300.00 6/22/2023Lonnel CoatsCEOBuy40,000$2.31$92,400.00 6/20/2023Jeffrey L WadeCFOBuy12,000$2.33$27,960.00 6/5/2023International S.C.A. ArtalDirectorBuy27,775,050$2.60$72,215,130.00 8/1/2022International S.C.A. ArtalDirectorBuy16,173,800$2.50$40,434,500.00 (Data available from 1/1/2013 forward) LXRX Insider Trading Activity - Frequently Asked Questions Who is on Lexicon Pharmaceuticals's Insider Roster? The list of insiders at Lexicon Pharmaceuticals includes International S.C.A. Artal, Jeffrey L Wade, Lonnel Coats, Raymond Debbane, and Wendy Mcdermott. Learn more on insiders at LXRX. What percentage of Lexicon Pharmaceuticals stock is owned by insiders? 6.80% of Lexicon Pharmaceuticals stock is owned by insiders. Learn more on LXRX's insider holdings. Which Lexicon Pharmaceuticals insiders have been buying company stock? The following insiders have purchased LXRX shares in the last 24 months: International S.C.A. Artal ($72,215,130.00), Jeffrey L Wade ($41,760.00), Lonnel Coats ($240,400.00), Raymond Debbane ($732,753.44), and Wendy Mcdermott ($35,340.00). How much insider buying is happening at Lexicon Pharmaceuticals? Insiders have purchased a total of 28,630,176 LXRX shares in the last 24 months for a total of $73,265,383.44 bought. Lexicon Pharmaceuticals Key ExecutivesMr. Jeffrey L. Wade J.D. (Age 59)President & COO Compensation: $752.05kMr. Brian T. Crum (Age 51)Senior VP, General Counsel & Secretary Compensation: $596.48kDr. Alan J. Main Ph.D. (Age 70)Executive Vice President of Innovation & Chemical Sciences Compensation: $576.96kDr. Craig B. Granowitz M.D. (Age 59)Ph.D., Senior VP & Chief Medical Officer Compensation: $652.48kDr. Michael Exton Ph.D. (Age 54)CEO & Director Ms. Kristen L. Alexander (Age 56)Vice President of Finance & Accounting Ms. Lisa M. DeFrancesco (Age 45)Vice President of Investor Relations, Corporate Strategy & Communications Mr. Dixon TerryVice President of ComplianceMs. Carrie SiragusaVice President of MarketingMs. Desiree GendronVice President of Sales & Training More Insider Trading Tools from MarketBeat Related Companies Ironwood Pharmaceuticals Insider Transactions Emergent BioSolutions Insider Transactions Rigel Pharmaceuticals Insider Transactions Sangamo Therapeutics Insider Transactions Codexis Insider Transactions XOMA Insider Transactions Vanda Pharmaceuticals Insider Transactions Verastem Insider Transactions Achieve Life Sciences Insider Transactions Regulus Therapeutics Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:LXRX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexicon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexicon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.